Browsing: Stock

Eli LillyLLY, the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for…

Costco Wholesale has delivered a strong 120.3% total return over the past 5 years, yet the stock now screens as expensive on broad valuation checks, which raises questions about how much of the story is already priced into the current US$944.32 share price

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand:…

Robert W. Eddy, President & CEO of BJ’s Wholesale Club Holdings, Inc. (NYSE:BJ), sold 73,016 shares of common stock on July 29, 2026, for a total value of ~$7.3 million. SEC Form 4 filing

Aurora Investment Managers LLC. lowered its stake in Equity Lifestyle Properties, Inc. (NYSE:ELS – Free Report) by 85.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,822 shares of the real estate investment trust’s stock after selling 46,469 shares during the…

(Bloomberg) — Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split

Planet Fitness (NYSE:PLNT), a franchisor and operator of low-cost fitness clubs, posted second-quarter revenue of $365.2 million, up 7.1% from a year ago, but the market was left wanting more as the stock dropped about 6.7% on Thursday. The biggest red flag was slowing momentum. Systemwide same-club sales grew just 1.7%, a sharp slowdown from…

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reaction underscored how sensitive investors are to clinical data, pipeline clarity, and competitive pressure from Eli Lilly’s obesity drugs. For you, this creates a chance to reassess exposure to companies tied…

What’s behind the move:The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter